(TOI) Oncology Institute - Ratings and Ratios

The Oncology Institute, Inc. (TOI) is a US-based oncology company providing comprehensive medical oncology services across the country. Its business is diversified into three segments: Dispensary, Patient Services, and Clinical Trials & Other, catering to adult and senior cancer patients. The companys service portfolio includes physician services, infusion and dispensary, clinical trials, radiation, and patient support services, along with educational programs and counseling.

From a business perspective, TOIs revenue streams are likely driven by its patient services, clinical trials management, and dispensary operations. Key performance indicators (KPIs) to watch include patient volume growth, revenue per patient, and clinical trials revenue as a percentage of total revenue. Additionally, metrics such as patient retention rates, customer satisfaction scores, and the number of clinical trials managed could provide insights into the companys operational efficiency and competitiveness.

TOIs growth prospects are tied to the increasing demand for oncology services, driven by the rising incidence of cancer in the US. The companys ability to expand its patient base, enhance its service offerings, and increase its clinical trials management business will be crucial to its future success. Key metrics to monitor include same-store growth, new patient acquisition rates, and the expansion of its clinical trials portfolio.

From a financial perspective, TOIs market capitalization stands at $235.30M, indicating a relatively small-cap stock. The absence of a P/E ratio suggests that the company is currently loss-making, which is not uncommon for growth-stage companies in the healthcare sector. Return on Equity (RoE) is significantly negative, indicating substantial losses relative to shareholder equity. Investors should closely monitor the companys cash burn rate, loss per share, and progress toward profitability.